How are Structure Therapeutics Ordinary Shares related to its American Depositary Shares (ADSs)?

Each American Depositary Share (ADS) of Structure Therapeutics represents three Ordinary Shares. The filing notes that the option exercise price reflects the fair market value per Ordinary Share, based on the trading price of the company’s ADSs on the grant date.

Structure Therapeutics grants options to director

Structure Therapeutics Inc. director Sharon Tetlow received a grant of options covering 39,453 Ordinary Shares.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Structure Therapeutics Inc. director Sharon Tetlow received a grant of options covering 39,453 Ordinary Shares. The options have an exercise price of $15.00 per share and expire on June 16, 2036. These options vest in equal monthly installments over the 12 months following June 17, 2026, and will be fully vested immediately before the company’s 2027 annual shareholder meeting. Each American Depositary Share represents three Ordinary Shares.

Insider Trade Summary

Grant/Award: 39,453 shares

Grant/Award 1 txn

Insider TETLOW SHARON

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (right to buy)	39,453	$0.00	$0.00

Holdings After Transaction: Share Option (right to buy) — 39,453 contracts (Direct)

Footnotes (3)

F1. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").
F2. The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting,
F3. The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.

Key Figures

Option grant size: 39,453 shares Exercise price: $15.00 per share Expiration date: June 16, 2036 +2 more

5 metrics

Option grant size 39,453 shares Ordinary Shares underlying options granted to director

Exercise price $15.00 per share Option exercise price for Ordinary Shares

Expiration date June 16, 2036 Option expiration for granted award

Vesting schedule 12 equal monthly installments Over 12 months following June 17, 2026

ADS ratio 1 ADS : 3 Ordinary Shares Representation of Ordinary Shares by ADSs

Key Terms

Share Option (right to buy), American Depositary Shares ("ADSs"), exercise price, vest in equal monthly installments, +1 more

5 terms

American Depositary Shares ("ADSs") financial

"based on the trading price of the Issuer's American Depositary Shares ("ADSs")"

American Depositary Shares (ADSs) are U.S.-listed certificates issued by a bank that represent ownership of a specified number of a foreign company’s ordinary shares, letting U.S. investors buy and sell those interests in U.S. dollars on American markets. They matter because they make investing in overseas companies as easy as buying a domestic stock—streamlining currency, settlement, and recordkeeping—while still exposing investors to foreign-market risks like exchange rates and local regulations.

exercise price financial

"The option exercise price per share is equal to the fair market value"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in equal monthly installments financial

"The shares vest in equal monthly installments over the 12 months"

Ordinary Shares financial

"The Ordinary Shares of the Issuer may be represented by ADSs."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Structure Therapeutics (GPCR) director Sharon Tetlow receive in this Form 4?

Sharon Tetlow received a grant of options to acquire 39,453 Ordinary Shares of Structure Therapeutics. The options are compensation-related, not an open-market purchase or sale, and give her the right to buy shares at a fixed exercise price in the future.

What is the exercise price and term of Sharon Tetlow’s options in GPCR?

The options have an exercise price of $15.00 per Ordinary Share and expire on June 16, 2036. This means she can choose to exercise the options at that price any time before expiration, subject to vesting conditions described in the grant.

How do Sharon Tetlow’s GPCR options vest over time?

The options vest in equal monthly installments over the 12 months following June 17, 2026. Regardless of monthly vesting, the grant will be fully vested immediately before Structure Therapeutics’ 2027 annual shareholder meeting, assuming the vesting conditions continue to be satisfied.

How many Structure Therapeutics shares underlie the options reported in this Form 4?

The grant covers 39,453 Ordinary Shares of Structure Therapeutics. After this grant, her reported derivative holdings from this award total the same 39,453 shares, reflecting the full number of shares subject to the option as disclosed in the filing.

Is this GPCR Form 4 a market buy or sell by Sharon Tetlow?

No, this Form 4 reports a compensation-related option grant, coded as an acquisition (A), not an open-market buy or sell. It records the award of derivative securities giving her the right to purchase Ordinary Shares in the future, subject to vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/18/2026 - 05:00 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TETLOW SHARON

(Last)

(First)

(Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Share Option (right to buy)	$15⁽¹⁾	06/17/2026		A		39,453		⁽²⁾	06/16/2036	Ordinary Shares	39,453⁽³⁾	$0	39,453	D

Explanation of Responses:

1. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").

2. The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting,

3. The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.

	/s/ Jun Yoon, Attorney-in-Fact	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR